Novo Nordisk to Buy Hypertension Treatment from for $1.3 Billion from KBP Biosciences

Dow Jones2023-10-16

Novo Nordisk A/S said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension.

Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease.

The Denmark-based biotechnology company said the drug is currently in a Phase 3 trial for uncontrolled hypertension and advanced chronic kidney disease.

“This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk.

The deal is expected to close before the end of 2023. Novo Nordisk’s U.S.-listed shares, which fell 0.8% in premarket trading, have run up 27.6% over the past three months through Friday, while the S&P 500 has slipped 3.9%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

CSK88
2023-10-16
CSK88
Good news

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2375118531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2023-10-16 19:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2375118531","market":"us","top_or_hot":-1,"title":"Novo Nordisk to Buy Hypertension Treatment from for $1.3 Billion from KBP Biosciences","media":"Dow Jones","content":"<html><head></head><body><p>Novo Nordisk A/S said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension.</p><p>Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease.</p><p>The Denmark-based biotechnology company said the drug is currently in a Phase 3 trial for uncontrolled hypertension and advanced chronic kidney disease.</p><p>“This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk.</p><p>The deal is expected to close before the end of 2023. Novo Nordisk’s U.S.-listed shares, which fell 0.8% in premarket trading, have run up 27.6% over the past three months through Friday, while the S&amp;P 500 has slipped 3.9%.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/70798cbe8d7c42357dc3e9e38d7fbd2c\" title=\"\" tg-width=\"845\" tg-height=\"824\"/></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novo Nordisk to Buy Hypertension Treatment from for $1.3 Billion from KBP Biosciences</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovo Nordisk to Buy Hypertension Treatment from for $1.3 Billion from KBP Biosciences\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-16 19:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/novo-nordisk-acquire-ocedurenone-uncontrolled-110000082.html><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Novo Nordisk A/S said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension.Ocedurenone is a pill that also has potential application for cardiovascular ...</p>\n\n<a href=\"https://finance.yahoo.com/news/novo-nordisk-acquire-ocedurenone-uncontrolled-110000082.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://finance.yahoo.com/news/novo-nordisk-acquire-ocedurenone-uncontrolled-110000082.html","article_id":"2375118531","we_media_id":"1012688067","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2375118531","pubTimestamp":1697454769,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":1,"id":"1012688067","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Bagsvrd, Denmark and Singapore, 16 October 2023 – Novo Nordisk A/S and KBP Biosciences PTE., Ltd. today announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to 1.3 billion US dollars.Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist  that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease . Uncontrolled hypertension is when a person’s blood pressure remains high despite taking two or more blood pressure-lowering treatments.“We look forward to adding ocedurenone to our pipeline as it will complement our current development programmes in cardiovascular disease and chronic kidney disease,” said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs at Novo Nordisk. “This deal is closely al","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4181":"酒店及度假村房地产投资信托","BK4007":"制药","BK4532":"文艺复兴科技持仓","NVO":"诺和诺德","BK4218":"酒店及度假村房地产信托","BK4585":"ETF&股票定投概念"},"translate_title":"诺和诺德以13亿美元从KBP生物科学公司收购高血压治疗公司","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVO":1},"content_text":"Novo Nordisk A/S said Monday it will pay $1.3 billion to KBP Biosciences to buy ocedurenone for uncontrolled hypertension.Ocedurenone is a pill that also has potential application for cardiovascular and kidney disease.The Denmark-based biotechnology company said the drug is currently in a Phase 3 trial for uncontrolled hypertension and advanced chronic kidney disease.“This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs,” said Camilla Sylvest, executive vice president of commercial strategy and corporate affairs at Novo Nordisk.The deal is expected to close before the end of 2023. Novo Nordisk’s U.S.-listed shares, which fell 0.8% in premarket trading, have run up 27.6% over the past three months through Friday, while the S&P 500 has slipped 3.9%.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":231108145971440,"gmtCreate":1697457266005,"gmtModify":1697457270568,"author":{"id":"3569730362364110","authorId":"3569730362364110","name":"CSK88","avatar":"https://static.tigerbbs.com/831855576c5b2d28ba9be7798d3c575e","vip":1,"crmLevel":3,"crmLevelSwitch":1,"idStr":"3569730362364110","authorIdStr":"3569730362364110"},"htmlText":"Good news","listText":"Good news","text":"Good news","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/231108145971440","repostId":2375118531,"repostType":2,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":4,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2375118531"}